NCT06592027 (Precedex) is a Phase 4 clinical trial of PRECEDEX INJ★ 2ML in Pressor Response, sponsored by Theodor Bilharz Research Institute.

Who is sponsoring NCT06592027?

NCT06592027 is sponsored by Theodor Bilharz Research Institute.

What drugs are being tested in NCT06592027?

Interventions in NCT06592027: PRECEDEX INJ★ 2ML, PRECEDEX INJ★ 2ML.

What condition does NCT06592027 study?

NCT06592027 studies Pressor Response.

Is NCT06592027 still recruiting?

NCT06592027 is currently completed. Last updated 19 September 2024.

Last reviewed 2024-09-19 · How we verify

NCT06592027: Precedex

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Dexmedetomidine for Attenuation of Pressor Response

Completed Phase 4 Last updated 19 September 2024

What this trial tests

Phase 4 trial testing PRECEDEX INJ★ 2ML in Pressor Response in 60 participants. Completed in 30 May 2024.

Timeline

1 February 2024

Primary endpoint
1 May 2024

30 May 2024

Quick facts

Lead sponsor	Theodor Bilharz Research Institute
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	60
Start date	1 February 2024
Primary completion	1 May 2024
Estimated completion	30 May 2024
Sites	1 location across Egypt

Drugs / interventions tested

PRECEDEX INJ★ 2ML — full drug profile →
PRECEDEX INJ★ 2ML — full drug profile →

Conditions studied

Pressor Response — all drugs for Pressor Response →

Sponsor

Theodor Bilharz Research Institute

Who can join

Adults 18 to 60, any sex, with Pressor Response. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Direct laryngoscopy and tracheal intubation are usually associated by hemodynamic changes due to increased sympathoadrenal activity which could precipitate serious negative effects in compromised patients . The pressor response could be blunted by dexmedetomidine which is a selective alpha 2 agonist which might provide hemodynamic stability during tracheal intubation.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of PRECEDEX INJ★ 2ML

Trials testing the same drug.

NCT06176222 — Combined Use of Naldebain® ER Injection and Precedex® After VATS · Phase 4 · unknown

Other Theodor Bilharz Research Institute trials

Trials by the same sponsor.

NCT06872138 — S100A8 in Serum and Urine as a New Biomarker in Lupus Nephritis · completed
NCT07262398 — Unilateral Intrathecal Bupivacaine Versus Prilocaine on Postoperative Spontaneous Voiding · Phase 4 · completed
NCT06414395 — The Effects of Different Loading Doses of Dexmedetomidine on The Bispectral Index-Guided Propofol Sedation in Patients U · Phase 4 · recruiting
NCT06541613 — Bilateral External Oblique Intercostal Plane Block in Laparoscopic Cholecystectomy · Phase 4 · completed
NCT07481812 — Prolapsed Hemorrhoids: Assessment of Various Surgical Modalities · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06592027 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Theodor Bilharz Research Institute
Last refreshed: 19 September 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06592027.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing